Health & Fitness
Health and FitnessHealth and Fitness 
Mon, February 21, 2011
Sun, February 20, 2011
Fri, February 18, 2011
EDMONTON, Feb. 18 /CNW/ - Isotechnika Pharma Inc. (TSX:ISA) is pleased to announce that Dr. Peter Wijngaard, Vice President, Innovation Leader, Research & Development at The Medicines Company, and Dr. Heung-Joon Yang, President, Global Network Services, Inc. have today joined the Board of Directors.
Isotechnika's President & CEO, Dr. Robert Foster commented, "We are excited to welcome these two highly qualified individuals to our Board. They both have a strong depth of relevant experience that can help Isotechnika as we move into Phase 3 for the prevention of kidney transplant rejection and progress our corporate development activities."
Dr. Wijngaard holds a Ph.D. in Immunology from Utrecht University, The Netherlands. Dr. Wijngaard formerly worked for F. Hoffmann-La Roche Ltd. (Basel, Switzerland.) as the Life Cycle Leader Transplantation for voclosporin, Cellcept, Zenapax, and DAC HYP. Dr. Wijngaard's past experience with the development of voclosporin in conjunction with his pharmaceutical industry background will be very beneficial to the Company.
Dr. Yang holds a Ph.D. in Bioengineering from University of Washington (Seattle, Washington, USA) and was the former CEO of LG Life Sciences, Ltd. Dr. Yang has a great deal of experience with cyclosporine analogues and has an in depth understanding of the Company's lead compound, voclosporin.
Both Dr. Wijngaard and Dr. Yang will serve on the Board's Audit Committee. To facilitate the appointment of the new members, Mr. Franklin Berger and Dr. Jurgen Engel have officially agreed to step down from the Company's Board of Directors effective immediately. The Company and the Board thank them both for their service as Directors.
About Isotechnika Pharma Inc.
Isotechnika Pharma Inc. is a biopharmaceutical company focused on the discovery and development of immunomodulating therapeutics designed to offer key safety advantages over currently available treatments. Its lead drug, voclosporin, is a calcineurin inhibitor, and is targeted at the estimated $3.0 billion market for this class of immunosuppressants.
Isotechnika Pharma Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika Pharma can be found at [ www.isotechnika.com ] or [ www.SEDAR.com ].
We seek safe harbor.